Pyruvate

metabolite

Pyruvate dysregulation reflects myocardial metabolic dysfunction and cardiomyocyte ischemia during acute MI.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencemedium

RationaleEnergetic/metabolic biomarker reflecting myocardial metabolic dysregulation and ischemic injury in AMI.

Also acts inMyocardial injury

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresIndeterminate

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-18.3

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationn/a

2anemia / acute blood lossn/a

3hypovolemia / dehydrationmag 1

4tachyarrhythmian/a

5hypoxemia / respiratory failuren/a

6hypertensive emergencymag 1

7high-demand / peri-operative stressmag 1

Coverage: 3/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 3 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum, plasma or urine

Collection tube

Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container

Method / principle

LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available

Reagent / substrate

Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent

Platform

LC-MS/MS; some automated chemistry

Turnaround · availability

Send-out / research · Specialized / research